Montelukast Normon (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Normon, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as directed by a healthcare professional, under medical supervision and appropriate monitoring.

GNH USA supplies Montelukast Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance through reliable logistics and dedicated customer support.

Montelukast acts on leukotriene pathways to control airway inflammation and bronchoconstriction.

Asthma: improves long‑term control of chronic asthma by reducing bronchoconstriction, airway edema and inflammatory cell infiltration. Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea caused by seasonal or perennial allergens. Exercise‑induced bronchoconstriction: prevents the acute narrowing of airways that occurs during or after physical exertion, allowing better exercise tolerance.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Abdominal pain or dyspepsia: occasional discomfort after dosing. - Nausea or vomiting: generally mild and self‑limiting. - Cough: non‑productive and transient. - Dizziness or fatigue: occasional, resolves with continued use.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression, anxiety or suicidal thoughts. - Hepatic enzyme elevation: rare cases of increased transaminases. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety aspects.

Assess asthma control: ensure baseline control before adding Montelukast. Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. Use with caution in hepatic impairment: dose adjustment may be required. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Montelukast can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase Montelukast plasma concentrations. - Phenobarbital or rifampin: may markedly reduce Montelukast exposure, compromising efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine, sertraline): may heighten risk of neuropsychiatric side effects. - Warfarin: potential alteration of INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilatory effect, may require dose adjustment of rescue inhalers.